Skip to main content
OpenTrials
Completed

NCT Number: NCT03176940

2-HOBA: Initial Evaluation in Humans

The purpose of this study is to evaluate the administration of single doses of 2-HOBA in humans, with an escalation of doses that begins with the calculated Maximum Recommended Starting Dose. This evaluation will assess tolerability to oral administration of 2-HOBA, obtain pharmacokinetic data, characterize the 2-HOBA metabolic pathways, and determine the relation of dose to prevention of formation of bi-functional electrophile adducts in blood. Characterization of the metabolic fate of 2-HOBA will be supported by investigations that evaluate metabolism in microsomes and cells.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

About this study

Consenting volunteers of at least 18 years old with no morbidity, including males, and females who are not pregnant will be recruited for the study. A maximum of 28 volunteers may be enrolled with a reasonable sampling of ethnicities from the Nashville area, and an effort will be made to recruit equal numbers of males and females. Additionally, an effort will be made to study as old a population as possible and to recruit relatively similar age groups for males and females. All volunteers will be admitted to the Vanderbilt Clinical Research Center (CRC) as inpatients.

A complete health history and physical examination will be conducted by a physician. Volunteers will be asked to collect and bring their first morning voided urine for baseline urinalysis. An EKG, baseline blood analysis, vital signs, and questions about feelings and adverse events will be asked prior to supplement administration. All tests will be repeated at various intervals throughout the 24-hour study period. A physician will oversee all clinical aspects of the study and will be responsible for all trial-related medical decisions. Pharmacokinetics will be studied through the blood analyses at intervals throughout the study and 24-hour urine collection after administration of the supplement.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy individuals older than 18;
  • Males and females who are not pregnant at the time of the study; and
  • Not taking any medication 2 weeks prior to and during the study.

Exclusion criteria

  • Inability to give informed consent;
  • Diseases that could manifest symptoms or signs that would confound interpretation of the relation between drug action and potential adverse effects;
  • Diseases that could manifest morbidity;
  • Known cardiac disease, kidney disease, or hepatic dysfunction;
  • The need to discontinue any drug that is administered as standard of care treatment; and
  • Unwillingness or inability to use approved birth-control methods.

Treatment and study plan

2-HOBA

Dietary Supplement

2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate

Other names: 2-Hydroxylbenzylamine

Primary outcomes

  1. Dose Tolerability

    Time frame: 24 hours

    Tolerability will be assessed by occurrence of Adverse Events (AEs). If AEs occur in 2 out of 6 volunteers, the dose will be declared not tolerated and the previous dose with no AEs will be declared maximum tolerable dose.

    AEs < 2: dose is tolerated AEs ≥ 2: dose is not tolerated

Sponsors and collaborators

Lead sponsor

Metabolic Technologies Inc.

Industry

Collaborators

  • National Institute on Aging (NIA)
  • Vanderbilt University

Registry information

Official study title

2-Hydroxybenzylamine: Initial Evaluation in Humans

Acronym: 2-HOBA

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jun 6, 2017
Registry last updated
Jun 4, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.